ClinicalTrials.gg
Active, not recruitingNCT01763554Updated Nov 3, 2026

Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014

An observational study in Neuroendocrine Tumors, NET, sponsored by AHS Cancer Control Alberta. Active, not recruiting at 1 site in Canada. Open to participants aged 14 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by AHS Cancer Control Alberta · Observational

How we know

Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
115
Ages
14 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Neuroendocrine Tumors with a site in Canada — 11 open to participants now, 20 under way, 4 of them phase 3. Neuroendocrine Tumors · Canada.

Started
2012
with 2 others
Observational
9 of 42
3 open now
Primary completion
2027-12
later than 14 of 19 live
Registered
8th of 42
by date
Lead sponsor
3 of 42
AHS Cancer Control Alberta

Among the 42 studies in Neuroendocrine Tumors with a site in Canada, this one is one of 3 that started in 2012, is one of 9 observational ones, reaches primary completion later than 14 of the 19 other live ones, and was the 8th registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

11 of the 42 studies in Neuroendocrine Tumors with a site in Canada are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 14 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Neuroendocrine Tumors with a site in Canada, or all of them as a file.
02

Study summary

Retrospective review of the medical files of 115 patients with neuroendocrine tumours who were treated with Lutetium-177 DOTA-TATE under Health Canada's Special Access Programme (SAP) at the Cross Cancer Institute between January 2010 and April 30, 2014. Efficacy, safety, and other relevant data will be collected to support a separate clinical trial application.

03

Conditions studied

  • Neuroendocrine Tumors, NET

Browse trials for

Keywords

  • Lu-177
  • Lutetium-177
  • DOTA-TATE
  • Neuroendocrine tumors
  • radiopharmaceutical
04

Who can participate

Ages eligible
14 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Limited to those subjects with neuroendocrine tumors who received Lu-177 DOTA-TATE treatment under SAP at the Cross Cancer Institute between January 2010 and April 30, 2014.

Eligibility criteria

Subjects with neuroendocrine tumours who received Lu-177 DOTA-TATE treatment under SAP at the Cross Cancer Institute between January 2010 and April 30, 2014.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
115 participants (estimated)
Patient registry
No

Interventions

  • DrugLu-177 DOTA-TATE

    The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.

06

What researchers measure

Primary outcomes

  1. Efficacy data on subjects with neuroendocrine tumours (NET) treated with Lu-177 DOTA-TATE

    Data (Radioisotope and CT/MRI images, blood assays and Quality of Life Questionnaires, pre and post treatment) will be collected to determine tumor response of subjects with NET after treatment with Lu-177 DOTA-TATE.

    Time frame: Retrospective data January 2010 - April 30, 2014

Secondary outcomes

  1. Safety and other relevant information on subjects treated with Lu-177 DOTA-TATE

    Safety data will include blood counts and chemistry, GFR and adverse events, pre and post treatment. Other data includes patient demographics.

    Time frame: Retrospective data January 2010 - April 30, 2014

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2012 (actual). Primary completion is estimated for Dec 2027, 184 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Dec 2025 → Dec 2027 and completion Dec 2025 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2012
First posted
Jan 9, 2013
StartActual
Aug 2012
Primary completionEst.
Dec 2027was Dec 2025
CompletionEst.
Dec 2027was Dec 2025
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2025→Dec 2027
Nov 3, 2026
Study completion
Dec 2025→Dec 2027
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Dec 2025→Dec 2027
    Study completion Dec 2025→Dec 2027
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT01763554
Collaborators
Cross Cancer Institute
Responsible party
Sponsor
First posted
Jan 9, 2013
Start date
Aug 2012
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Donald Morrish, MD, PhD
principal investigator · Endocrinology & Oncology, University of Alberta, Cross Cancer Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion